We investigated the effect of recombinant human transforming growth factor .82 (rhTGF-J32) administration on trabecular bone loss induced by unloading in rats. Hind limb suspension for 14 d inhibited bone formation and induced osteopenia as shown by decreased bone volume, calcium and protein contents in long bone metaphysis. Systemic infusion of rhTGF-P2 (2 jug/kg per day) maintained normal bone formation rate, and prevented the decrease in bone volume, bone mineral content, trabecular thickness and number induced by unloading. In vitro analysis of tibial marrow stromal cells showed that rhTGF-f32 infusion in unloaded rats increased the proliferation of osteoblast precursor cells, but did not affect alkaline phosphatase activity or osteocalcin production. Northern blot analysis of RNA extracted from the femoral metaphysis showed that rhTGF-fi2 infusion in unloaded rats increased steady-state levels of type I collagen mRNA but not alkaline phosphatase mRNA levels. rhTGF-P2 infusion at the dose used had no effect on metaphyseal bone volume and formation, osteoblast proliferation or collagen expression in control rats. The results show that systemic administration of rhTGF-l2 enhances osteoblast precursor cell proliferation and type I collagen expression by osteoblasts, and prevents the impaired bone formation and osteopenia induced by unloading. (J. Cln. Invest. 1995. 
Introduction
The maintenance and renewal of the skeletal tissue are controlled by mechanical forces exerted by loading and by systemic and local factors affecting bone cell recruitment and activity. Experimental and clinical observations indicate that skeletal unloading is associated with inhibition of bone formation (1, 2) . The cellular and molecular mechanisms involved in the decreased bone formation induced by skeletal unloading are, however, poorly understood. We previously reported that skeletal unloading induced by removal of weight bearing in rats is associated with impaired proliferation of osteoblast precursor cells in the marrow stroma (3) . Unloading was also found to reduce the osteogenic capacity of osteoblast precursor cells in rat bone marrow (4) . A decreased production of mRNA for bone matrix proteins was also found in disuse osteopenia in rats (5) , suggesting that the decreased bone formation induced by removal of mechanical forces on the skeleton involves alteration of osteoblast progenitor cell recruitment and/or defective function of differentiated osteoblasts.
Local factors acting on the recruitment and function of cells of the osteoblast lineage are likely to play a central role in the induction of osteogenesis by loading. Experimental studies suggest that prostaglandins may be involved in the strain-induced osteogenesis in vitro and in vivo (6) (7) (8) . Other local factors, however, may be implicated since prostaglandins stimulate the production of insulin-like growth factor-I (IGF-I) by osteoblasts (9) . Recently, we have reported that IGF-I stimulates bone formation, increases trabecular bone mass and marrow-derived osteoblastic cell proliferation in non-weight-bearing rat bones. However, IGF-I treatment does not totally prevent the decreased bone formation and osteopenia in unloaded rats (10) . We, therefore, postulated that other factors which promote osteoblastic cell growth and differentiation might prevent the inhibitory effect of unloading on bone formation.
Transforming growth factor-/3 (TGF-/3s) are multifunctional polypeptides that affect many cell types (11, 12) . TGFPs appear to play a major role in the regulation of bone formation. TGF-f3s are produced by osteoblasts (13) , stored in large amount in the bone matrix ( 14) , and are potent factors affecting the growth and differentiation of osteoblastic cells (15) . How- ever, the effects of TGF-,fs may differ depending on TGF-/3 concentration, cell density, origin and maturational stage of osteoblastic cells (15) . TGF-/3s have chemotactic (16) and mitogenic effects on normal rodent and human osteoblastic cells (13, (17) (18) (19) (20) . In addition, TGF-,fs modulate gene expression and production of noncollagenous bone matrix proteins (21, 22) , enhance steady state levels of collagen mRNA and collagen synthesis (18) and stimulate bone formation in vitro (23) . In vivo, local injections of TGF-f31 or TGF-/3-2 in rodent calvaria (24) (25) (26) (27) (28) or femur periosteum (29) accelerate bone formation and induce closure of skull defects (30) , indicating that TGFP6s are potent stimulators of periosteal bone formation. How- ever, few studies have tested the effects of TGF-/3 on endosteal bone in vivo. Intermittent administration of TGF-L2 was found to stimulate endosteal bone formation in rats (31 ) and to inhibit bone resorption in ovariectomized rats (32) . However, TGF-/B2 has no effect on trabecular bone loss induced by ovariectomy (32) , perhaps due to the short half life of TGF-f3 in vivo (33 (34) . After dehydratation in ethanol, the femurs were cut in half, the dry metaphyseal bone was carefully collected by scrapping, weighed and dissolved in 5% trichloroacetic acid (TCA) for 24 h. The total calcium (kit BioMerieux, France) and protein contents (35) (36) were measured in the proximal metaphyseal area of the tibia in a standardized zone (3.6 mm2) at distance (500 jrm) from the growth plate: the trabecular bone volume (percent bone tissue composed of calcified and uncalcified matrix), the trabecular thickness (average of all trabecular thickness, um), the trabecular density (number of trabeculae per mm2), the osteoid surface (percent trabecular bone surface covered with uncalcified bone matrix), the osteoblast surface (percent trabecular surface covered with osteoblasts), the resorption surface (percent trabecular surface covered with eroded lacunae and osteoclasts), and the number of osteoclasts per mm of trabecular bone surface. The mineral apposition rate (mean distance between the double fluorescent labels divided by the interval labeling time, and the doublelabeled surface (percent of the bone surface with double fluorescent markers) were also measured. The bone formation rate at the tissue level was calculated by multiplying the mineral apposition rate by the double fluorescent-labeled surface (36). The mean cortical thickness was measured along 500 pm of the two cortices in the tibial diaphysis at distance (4 mm) of the growthplate.
Proliferation of marrow stroma-derived cell cultures. To determine the effects of rhTGF-,62 on osteoblast precursor cells, marrow stromal cells were isolated from the left tibia of each treated or untreated rat, as previously described (37). The tibia was cleaned of soft tissues and aseptically dissected in sterile phosphate-buffered saline (PBS). After removal of the epiphyseal area, the tibias were cut transversally, the marrow was flushed out with PBS and collected. After centrifugation, the bone marrow cell pellets were suspended in DME supplemented with antibiotics (100 IU/ml penicillin and 100 Ag/ml streptomycin).
The cells were then dispersed by passage through a fine metal mesh, counted and plated in 25-cm2 flasks at the same initial density. After 12 d of culture in DME with 10% FCS, confluent cells were detached with 0.05% trypsin, and counted. To determine the proliferation rate of marrow stromal cells, the cells were plated at 5,000 cells/cm2 in multiwell chambers (LabTek, Nunc) and cultured in DME with 10% FCS. 1 d after plating, the medium was replaced and the cells were cultured for five days. At day 1, 3, and 5 of culture, the medium was removed, the cells were washed with PBS, fixed in 70% ethanol at 4TC and stained cytochemically for alkaline phosphatase activity (ALP) to identify osteoblast precursors in the marrow stroma (38) . The total number of marrow stromal cells and ALP-positive (ALP+) cells was counted in the total surface (1 cm2) area of four wells per rat per timepoint using a Zeiss II eyepiece integrator mounted on a microscope ocular (3). Alkaline phosphatase activity and osteocalcin production. ALP activity and osteocalcin production, two parameters of osteoblast differentiation (39) , were determined in confluent marrow stromal cells isolated from treated and untreated rats with rhTGF-,/2. Bone marrow stromal cells were plated at 5,000 cells/cm2 in six-well plates (Falcon), cultured until confluence in DME with 10% FCS, and then cultured for 2 d in serum-free medium. The medium was removed and frozen for osteocalcin determination. The cells were rinsed with cold PBS, scraped in distilled water, sonicated and ALP activity in the cell lysate was determined by a colorimetric method (BioMerieux, France) and corrected for cell protein content (BioRad). Osteocalcin levels released in the medium were measured by a specific radioimmunoassay using a specific rabbit rat osteocalcin antibody (40) . The intra-and inter-variabilities of the assay are 6 and 7%, respectively (40) .
RNA extraction and Northern blot analysis. The left femur was removed from each treated and untreated rat and the metaphysis was rapidly dissected under sterile conditions and washed in PBS to remove marrow cells. Total RNA was extracted using the guanidinium thiocyanate-phenol-chloroform method (41) 2500; General Corp., Ann Arbor, MI) and the integrated area under the curve for each signal was standardized against the signal for 18 S rRNA.
Statistics. All data are expressed as mean±SE. The results obtained from the two separate experiments were found to be not statistically different. The data were pooled and analyzed by two-factor analysis of variance (ANOVA) using the statistical package super-ANOVA (Macintosh, Abacus Concepts, Inc., Berkeley, CA). When significant interactions were indicated, differences between control and unloaded rats, and between untreated and TGF-,l treated rats, were evaluated by a multiple comparison procedure (Fisher's test) with a minimal significance of P < 0.05.
Results
Systemic rhTGF-/32 prevents osteopenia in unloaded rats. Skeletal unloading for 14 d induced a marked decrease in metaphyseal bone volume in tibia of suspended rats compared to controls (Figs. 1 and 2 A). This metaphyseal osteopenia was associated with a marked reduction in the trabecular thickness and number in unloaded rats compared to controls (Fig. 2, B and C) . Osteopenia induced by unloading was also demonstrated by low trabecular bone weight, and decreased bone calcium and protein contents in the femoral metaphysis compared to that of controls (Table I) .
The infusion of rhTGF-f32 in unloaded rats prevented the decrease in metaphyseal bone volume induced by unloading ( Figs. 1 and 2 A) . The amount of bone matrix and orientation of trabeculae were similar in unloaded-treated rats and in controls (Fig. 1) . Prevention of metaphyseal bone loss resulted from maintenance of normal trabecular thickness and number, the latter being increased above control values in unloaded rats treated with rhTGF-32 (Fig. 2, B and C) . rhTGF-/32 infusion completely prevented the decrease of metaphyseal bone weight, bone calcium content and bone protein content induced by unloading in femur (Table I ). In contrast, systemic rhTGF-162 administration in control rats had no effect on bone volume, number, and thickness of trabeculae in the tibial metaphysis (Fig. 2) , and had no effect on metaphyseal bone calcium and protein contents in femur (Table I) .
The preventing effect of rhTGF-f32 on metaphyseal bone loss in unloaded rats was not associated with change in skeletal growth. The administration of rhTGF-,B2 had no significant effect on body weight, tibia length and cortical thickness in unloaded rats (Table H) , indicating that rhTGF-,62 administration at the dose used had no stimulatory effect on body or longitudinal bone growth. However, systemic administration of rhTGF-/32 induced a modest (6%, P < 0.05) increase in the diaphyseal cortical thickness in control rats, suggesting a slight stimulation of periosteal bone formation in this group (Table  II) . These results indicate that the preventive effect of systemic administration of rhTGF-f32 on metaphyseal bone loss in unloaded rats did not result from change in bone growth.
Systemic rhTGF-f32 prevents the impaired bone formation and reduces indices of bone resorption in unloaded rats. Unloading induced a marked inhibition of bone formation in the tibial metaphysis. This was demonstrated by the decrease in the extent of trabecular bone surface with osteoblasts and the decrease in the extent of double calcein labeled surface compared to control rats (Fig. 3) . The bone formation rate was 39% lower in unloaded than in control rats, and this resulted in a marked reduction of osteoid surface in unloaded rats compared to controls (Table III) . The systemic administration of rhTGF-,62 in unloaded rats completely prevented the decrease in the amount of osteoid induced by unloading (Table HI) .
This resulted from the enhancing effect of rhTGF-,82 on the osteoblast surface (+67%) and on the double-labeled surface (+89%) which remained normal, or were increased above control values (Fig. 3) . However, rhTGF-f32 had no significant effect on the mineral apposition rate or osteoid thickness (Table   III) . Systemic administration of rhTGF-,32 in unloaded rats increased the bone formation rate by 92.5% compared with untreated unloaded rats, and this parameter was increased above control values (Fig. 3) . In contrast to this marked anabolic effect of rhTGF-32 in unloaded rats, rhTGF-32 infusion in control rats had no effect on static and dynamic histomorphometric indices of bone formation in the tibial metaphysis ( (38) . The effect of systemic administration of rhTGF-f32 on total and ALP+ stromal cells was determined in vitro during the period of active cell growth (3 d) and at pre-confluence (5 d). At one day of culture, the total number of marrow stroma-derived cells was similar in control and unloaded rats, treated or not with rhTGF- (Fig. 5 A) . We found that rhTGF-/32 infusion in unloaded rats increased the total number of marrow derived- infusion in control rats did not affect the number of marrow stromal cells or the number of ALP+ cells (Fig. 5 B) , indicating that rhTGF-,f2 at the dose used had no effect on osteoblast precursor cell proliferation in control rats.
We then evaluated whether rhTGF-,62 administration affected alkaline phosphatase activity and osteocalcin production in marrow stromal cells derived from unloaded and control rats.
rhTGF-,32 administration induced a non significant (P = 0.26) decrease in ALP activity in control rats. The mean alkaline phosphatase activity and osteocalcin production by bone marrow-derived cells in vitro were not significantly different in unloaded rats and rhTGF-f32-treated unloaded rats (Table IV) , indicating that the increased proliferation of ALP+ cells induced by rhTGF-,32 in unloaded rats was not associated with changes in ALP activity or osteocalcin production per cell. (Fig. 6 A) . The steady-state levels of type I collagen mRNA corrected for RNA loading were 30% lower in unloaded rats compared to controls. rhTGF-162 infusion induced a twofold increase in the mean levels of steady-state type I collagen mRNA levels (Fig. 6, A and B) . In contrast, rhTGF-j32 administration did not change ALP mRNA levels in unloaded rats (Fig. 6, A and C) . In addition, rhTGF-/32 infusion in control rats had no effect on type I collagen or ALP mRNA levels (Fig. 6 ). These results indicate that the systemic administration of rhTGF-,62 increased the expression of type I collagen by osteoblasts in the femoral metaphysis of unloaded rats.
Discussion
To our knowledge, this is the first report showing that the endosteal bone loss in an experimental model of osteopenia can be prevented by the systemic administration of a growth factor which stimulates trabecular bone formation, increases osteoblast recruitment and enhances collagen expression by osteoblasts in vivo. Since the in vivo half-life.of TGF-f3 is very short (33), we used a continuous administration of rhTGF-,82 to ensure constant delivery of the compound. The dose of rhTGF-,62
administered in the present study is lower than the amount of TGF-,B reported to stimulate endosteal bone formation by multiple local injections in rats (31, 32) . It is noteworthy that, at the low dose used, rhTGF-f2 infusion was effective in maintaining normal trabecular bone formation and bone mass in unloaded rats without affecting longitudinal bone growth. (50) (51) (52) (53) . The cellular mechanisms implicated in the mitogenic effects of TGF-/3 on osteoblastic cells may involve an increased production of PDGF (54) . In addition, TGF-/3 may have direct effects on osteoblastic cell growth through induction of the expression of c-fos (55) and c-jun proto-oncogenes (51) .
We also found that rhTGF-/32 administration in unloaded rats increased type I collagen mRNA levels in the metaphysis.
The increased collagen expression found in rhTGF-/32-treated unloaded rats is in accordance with the stimulatory effect of TGF-/3 on type I collagen mRNA levels in fibroblasts (56) and osteoblastic cell cultures (18, 57) . Although TGF-P was found to inhibit collagen expression in long-term developing rat calvaria cell cultures, this appears to occur secondarily to induction of cell growth (50, 51) . The increased collagen expression induced by rhTGF-/32 infusion may have resulted from multiple transcriptional, posttranscriptional and posttranslational effects (57) since TGF-P increases procollagen transcription (58) and procollagen mRNA stability (59, 60) . This increased collagen expression may have in part contributed to the anabolic effect of rhTGF-/32 on metaphyseal bone formation in unloaded rats. However, the lack of significant change in the appositional rate suggests that the increased bone formation induced by rhTGF-/32 was mainly related to the increased number of osteoblasts in the metaphysis. In contrast to type I collagen, ALP mRNA levels were not changed in the metaphysis of rhTGF-/32-treated unloaded rats. Previous studies indicate that ALP mRNA levels do not correlate with bone matrix deposition whereas steadystate mRNA levels for collagen often reflect osteoblast activity (61) . On the other hand, rhTGF-/32 infusion may have increased the expression of bone matrix proteins (22, 60, 62), induced chemotactic attraction of osteoblast precursors (16), inhibited the degradation of the extracellular matrix (63) and autoinduced TGF-/3 expression by osteoblasts (64) , which may have contributed to the observed stimulatory effect of rhTGF-/32 on bone formation in unloaded rats.
Although the cellular and molecular effects of TGF-,/ on bone cells in vivo are likely to be complex, our findings indicate that the prevention of the impaired bone formation and trabecular bone loss by rhTGF-/32 infusion in unloaded rats is associated with stimulation of osteoblast precursor cell proliferation and increased expression of type I collagen by metaphyseal osteoblasts. These results are consistent with previous indications showing that TGF-,/ is an important mediator of soft and hard tissue repair (30, 65, 66) . The finding that the systemic administration of a growth factor which exerts anabolic effects on bone cells, can prevent the trabecular bone loss in an animal model of osteopenia may be of significant clinical importance. Further experimental studies will determine whether the systemic administration of TGF-,/ alone, or in combination with other osteogenic factors, or the single injection of TGF-,B (65) , may be of therapeutic interest to enhance the endosteal bone formation and to maintain bone integrity in osteopenic disorders.
